Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)
MWN-AI** Summary
Beyond Air, Inc. (NASDAQ: XAIR), a company focused on innovative medical devices and biopharmaceuticals utilizing nitric oxide for medical treatments, announced a significant advancement in its commercial strategy on April 1, 2026. The company secured a national group purchasing agreement with a prominent U.S. group purchasing organization (GPO), enabling member hospitals and health systems to purchase the LungFit® PH system, an inhaled nitric oxide therapy aimed at enhancing patient care.
This agreement marks a pivotal expansion of access to LungFit PH, benefiting nearly 2,000 additional U.S. hospitals and health systems. Robert Goodman, CEO of Beyond Air, emphasized the importance of their partnerships with leading GPOs like Vizient and Premier, Inc., which collectively streamline the procurement process for healthcare providers seeking efficient, cost-effective alternatives to traditional nitric oxide delivery methods.
The LungFit PH platform leverages proprietary Plasma Pulse Technology® to produce nitric oxide on demand from ambient air, eliminating the reliance on bulky supply tanks. This innovation not only simplifies clinical workflows but also alleviates supply chain challenges, aligning with hospital sustainability efforts.
Beyond Air's recent GPO agreement further solidifies its commitment to expanding the reach of LungFit PH and facilitating the adoption of its advanced solution among healthcare providers across the United States. The company’s continued growth is supported by FDA approval and the CE Mark for the LungFit PH system, targeting the treatment of term and near-term neonates with hypoxic respiratory failure.
As the company positions itself for broad market adoption, it faces inherent risks and uncertainties typical of growth in the biopharmaceutical sector, as highlighted in its forward-looking statements. For further information, stakeholders are encouraged to consult Beyond Air’s official website.
MWN-AI** Analysis
Beyond Air, Inc. (NASDAQ: XAIR) is making significant strides in the healthcare marketplace with its recent agreement with a top three national group purchasing organization (GPO). The deal, effective April 1, 2026, not only solidifies Beyond Air’s position in the inhaled nitric oxide therapy sector but also enhances its access to nearly 2,000 additional U.S. hospitals and health systems. Given this expansion, investors should closely monitor the company’s momentum and potential growth trajectory.
The LungFit® PH system, which utilizes innovative Plasma Pulse Technology® to generate nitric oxide on demand, offers a compelling solution that aligns with current healthcare trends towards efficiency and sustainability. As hospitals strive to optimize their supply chains and reduce costs, Beyond Air’s tankless system could emerge as a preferred choice over traditional delivery methods. The endorsement by GPOs provides a validated route for hospitals to adopt this technology, which could translate into increased sales and revenue growth for Beyond Air.
However, while the initial response to this GPO agreement is likely positive, investors should also remain cognizant of potential risks. The company’s dependence on successful execution of its commercial strategy and the ability to maintain strong relationships with healthcare providers could pose challenges. Additionally, the biotechnology sector is known for its volatility, and fluctuations in regulatory approvals or market acceptance could impact performance.
In conclusion, Beyond Air’s strategic partnership represents a strong opportunity for investors looking to capitalize on innovations in medical device technology. With a focused approach to reaching healthcare providers and aligning with the industry's shift toward more efficient solutions, Beyond Air could deliver significant returns. Nonetheless, a close eye on market dynamics and company disclosures will be critical for informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
GARDEN CITY, N.Y., April 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients’ lives, today announced it has been awarded a national group purchasing agreement for inhaled nitric oxide therapy with a leading U.S. group purchasing organization (GPO). Effective April 1, 2026, the agreement allows participating member hospitals and health systems to access the LungFit® PH system.
This new agreement builds on Beyond Air’s existing relationships with leading U.S. GPOs, including Vizient and Premier, Inc., further expanding access to a broad network of healthcare providers in the United States.
“Our GPO relationships play an important role in expanding access to LungFit PH, and this additional agreement meaningfully increases our reach by nearly 2,000 U.S. hospitals and health systems,” said Robert Goodman, Chief Executive Officer of Beyond Air. “By establishing purchasing agreements with three of the largest U.S.-based GPOs, we have created a more streamlined pathway for providers to evaluate and adopt a tankless nitric oxide solution. The endorsement of these GPOs not only expands our commercial reach, it also helps accelerate adoption as hospitals seek more efficient, cost-effective alternatives to traditional nitric oxide delivery systems.”
The LungFit PH platform utilizes patented Plasma Pulse Technology® to generate nitric oxide on demand from room air. By eliminating the need for traditional source supplies, LungFit PH supports simplified clinical workflows, reduced supply chain burden, and hospital sustainability initiatives.
This latest GPO agreement reinforces Beyond Air’s continued momentum in expanding access to LungFit PH through leading group purchasing organizations and supporting hospitals in delivering high-quality, cost-effective care.
About Beyond Air, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visit www.beyondair.net.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company’s expectations related to the commercial growth, market adoption of LungFit PH, expansion in the U.S. and international markets, and the Company’s long-term strategic and financial performance. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “potential,” “will,” “would,” “could,” “may,” and similar expressions, or by the use of future tense. These statements are based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management.
Because forward-looking statements relate to future events, they are subject to inherent risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s ability to successfully execute its commercial strategy, achieve market adoption of its products, maintain and expand customer relationships, manage leadership transitions effectively, obtain additional financing, and other risks described in the “Risk Factors” section of Beyond Air, Inc.’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission.
CONTACTS:
Investor Relations contact
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
(212) 915-2577
FAQ**
How does Beyond Air Inc. XAIR plan to leverage its new national group purchasing agreement to enhance the adoption of the LungFit PH system among hospitals and health systems in the U.S.?
What impact does Beyond Air Inc. XAIR anticipate the endorsement from leading group purchasing organizations will have on its market share and growth potential in the inhaled nitric oxide therapy sector?
Can you elaborate on the competitive advantages that the LungFit PH system provides Beyond Air Inc. XAIR over traditional nitric oxide delivery systems within the healthcare market?
What are the key risks and uncertainties that Beyond Air Inc. XAIR identifies in executing its commercial strategy for the LungFit PH platform, especially following this recent GPO agreement?
**MWN-AI FAQ is based on asking OpenAI questions about Beyond Air Inc. (NASDAQ: XAIR).
NASDAQ: XAIR
XAIR Trading
-21.15% G/L:
$0.4881 Last:
391,202 Volume:
$0.558 Open:
